Avrum Spira

This inventor holds 16 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Lung Cancer Diagnostics. Top assignees: Boston University, British Columbia Cancer Agency Branch, The University of British Columbia. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Avrum Spira. Retrieved from https://idiyas.com/inventor/avrum-spira

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 18)

% Patents Active = 87.5

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 14)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 36(Granted Patents)

Company Filing History:

British Columbia Cancer Agency Branch

patents

2 out of 963

The University of British Columbia

patents

4. 1 out of 314

Health Research, Inc.

patents

5. 1 out of 1,687

University of Utah Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Nasal Epithelium

Gene Expression

Lung Cancer

Biomarker

Chronic Obstructive Pulmonary Disease

Emphysema

Diagnostic Methods

Prognostic Methods

Bronchial Lesions

Lung Function

Risk Identification

Class Prediction

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577620 - Nasal epithelium gene expression signature and classifier for the prediction of lung cancer (2026-03-17),

2. 12329771 - Methods relating to lung cancer (2025-06-17),

3. 12329759 - Methods and compositions relating to lung function (2025-06-17),

4. 11977076 - Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells (2024-05-07),

5. 11579140 - Methods related to bronchial premalignant lesion severity and progression (2023-02-14),

6. 11426423 - Methods relating to lung cancer (2022-08-30),

7. 10927417 - Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions (2021-02-23),

8. 10808285 - Diagnostic for lung disorders using class prediction (2020-10-20),

9. 10632140 - Methods relating to lung cancer (2020-04-28),

10. 10570454 - Methods of identifying individuals at increased risk of lung cancer (2020-02-25),

11. 10533225 - Methods and systems for monitoring, diagnosing, and treating chronic obstructive pulmonary disease (2020-01-14),

12. 10314855 - Methods relating to lung cancer (2019-06-11),

13. 10233498 - Therapeutic agent for emphysema and COPD (2019-03-19),

14. 9920374 - Diagnostic for lung disorders using class prediction (2018-03-20),

15. 9677138 - Methods and systems for monitoring, diagnosing, and treating chronic obstructive pulmonary disease (2017-06-13),

Title: Innovator Spotlight: Avrum Spira - Revolutionizing Lung Disorder Diagnostics

Introduction:

Avrum Spira, a distinguished inventor hailing from Newton, MA, has made significant contributions to the field of healthcare with his groundbreaking innovations in diagnosing and prognosing lung disorders. With an impressive portfolio of 13 patents, Spira's latest inventions focus on leveraging gene expression profiles from nose epithelial cells to enhance the accuracy and non-invasiveness of lung cancer diagnostics.

Latest Patents:

Spira's recent patents showcase his commitment to advancing diagnostics for lung disorders. One such patent highlights diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells. These methods offer a less invasive and more accurate approach to detecting lung cancer compared to existing diagnostic techniques. Additionally, Spira's innovations extend to methods related to bronchial premalignant lesion severity and progression, emphasizing the importance of early detection and personalized treatment strategies.

Career Highlights:

Throughout his career, Avrum Spira has been associated with reputable institutions such as Boston University and the British Columbia Cancer Agency Branch. His expertise and innovative spirit have led to the development of cutting-edge technologies that have the potential to revolutionize the field of healthcare. Spira's dedication to advancing lung disorder diagnostics underscores his passion for improving patient outcomes and quality of life.

Collaborations:

In his pursuit of excellence, Avrum Spira has collaborated with accomplished professionals in the industry, including Marc Elliott Lenburg and Joshua David Campbell. These collaborations have been instrumental in driving forward innovative research and development initiatives aimed at addressing unmet needs in the diagnosis and treatment of lung disorders. By working alongside talented individuals, Spira has been able to broaden the impact of his inventions and further cement his legacy as a trailblazer in the field of healthcare innovation.

Conclusion:

In conclusion, Avrum Spira's relentless pursuit of innovation and his commitment to transforming lung disorder diagnostics have established him as a visionary inventor in the healthcare industry. His latest patents reflect his dedication to improving patient care through advanced diagnostic technologies, setting a new standard for precision medicine in the field of respiratory health. As Spira continues to push the boundaries of innovation, his contributions are poised to make a lasting impact on the lives of individuals affected by lung disorders worldwide.

Profile summary based on public USPTO records.